Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging--prediction of patient clinical response.

PURPOSE To determine retrospectively whether relative cerebral blood volume (CBV) measurements can be used to predict clinical response in patients with low-grade gliomas. MATERIALS AND METHODS Approval for this retrospective HIPAA-compliant study was obtained from the Institutional Board of Research Associates, with waiver of informed consent. Thirty-five patients (23 male and 12 female patients; median age, 39 years; range, 4-80 years) with histologically diagnosed low-grade gliomas (21 low-grade astrocytomas and 14 low-grade oligodendrogliomas and low-grade mixed oligoastrocytomas) were examined with dynamic susceptibility-weighted contrast material-enhanced perfusion magnetic resonance (MR) imaging. Wilcoxon tests were used to compare patients in different response categories (complete response, stable, progressive, death) with respect to baseline relative CBV. Kaplan-Meier survival curves, log-rank tests, and Weibull survival models were used to characterize and evaluate the association of baseline relative CBV with time to progression. Tumor volumes and relative CBV measurements were obtained at initial examination and follow-up. RESULTS Lesions with relative CBV less than 1.75 had a median time to progression of 4620 days +/- 433 (standard deviation), and lesions with relative CBV more than 1.75 had a median time to progression of 245 days +/- 62. Patients who had an adverse event (either death or progression) had significantly higher (P = .003) relative CBV than did patients without adverse events (either complete response or stable disease). Lesions with low baseline relative CBV had stable tumor volumes at follow-up over time, whereas those with high baseline relative CBV (>1.75) had progressively increasing tumor volumes over time. CONCLUSION Dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging can help to identify low-grade gliomas that will progress rapidly and a subset of low-grade gliomas that have a propensity for malignant transformation.

[1]  J. Piepmeier,et al.  Low-grade gliomas: Introduction and overview , 1997, Journal of Neuro-Oncology.

[2]  B. Fisher,et al.  Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A Leviton,et al.  Limitations of the World Health Organization classification of childhood supratentorial astrocytic tumors , 2000, Cancer.

[4]  G Johnson,et al.  Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. , 1999, Radiology.

[5]  Chun-Jung Juan,et al.  Discrepant MR spectroscopic and perfusion imaging results in a case of malignant transformation of cerebral glioma. , 2002, AJNR. American journal of neuroradiology.

[6]  Michael H Lev,et al.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. , 2004, AJNR. American journal of neuroradiology.

[7]  E F Halpern,et al.  Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. , 1994, Radiology.

[8]  B. D. Ward,et al.  Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis. , 2004, AJNR. American journal of neuroradiology.

[9]  Glyn Johnson,et al.  Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. , 2002, Radiology.

[10]  M. Bernstein,et al.  The Role of Surgery in Low Grade Gliomas , 1999, Journal of Neuro-Oncology.

[11]  Mark S. Cohen,et al.  Contrast agents and cerebral hemodynamics , 1991, Magnetic resonance in medicine.

[12]  J. Piepmeier,et al.  Observations on the current treatment of low-grade astrocytic tumors of the cerebral hemispheres. , 1987, Journal of neurosurgery.

[13]  L. Astrakas,et al.  Spectroscopic and perfusion magnetic resonance imaging predictors of progression in pediatric brain tumors , 2004, Cancer.

[14]  D. Pickuth,et al.  The management of histologically unverified presumed cerebral gliomas with radiotherapy. , 1994, International journal of radiation oncology, biology, physics.

[15]  Douglas C. Miller,et al.  Treatment and Survival of Low-Grade Astrocytoma in Adults--1977–1988 , 1992 .

[16]  H. Mehdorn,et al.  Glioblastoma multiforme-report of 267 cases treated at a single institution. , 2005, Surgical neurology.

[17]  Mitchel S. Berger,et al.  Low grade gliomas: Functional mapping resection strategies, extent of resection, and outcome , 1997, Journal of Neuro-Oncology.

[18]  Glyn Johnson,et al.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.

[19]  Jin-Suh Kim,et al.  Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results. , 2002, AJR. American journal of roentgenology.

[20]  B. Rosen,et al.  Perfusion imaging with NMR contrast agents , 1990, Magnetic resonance in medicine.

[21]  Glyn Johnson,et al.  Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. , 2004, AJNR. American journal of neuroradiology.

[22]  M Takahashi,et al.  Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. , 1998, AJR. American journal of roentgenology.

[23]  M. Prados,et al.  Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.